• Paratek Pharmaceuticals Inc.



    PRTK

    나스닥 초소형

  • http://www.paratekpharm.com
    관심종목 등록하기
  • 종합점수

    57

  • 모멘텀점수

    53

  • 펀더멘탈점수

    62

  • 베타

    0.74

  • 롱텀

     
     

    14

  • 엔벨

     
     

    40

섹터 헬스케어 산업 제약 및 생명공학
Paratek Pharmaceuticals Inc was incorporated in Delaware in 2001. It is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. The Company uses its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Its two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline is ready to advance into Phase 3 the final stage of clinical development and sarecycline entered Phase 3 clinical development. The Companys first late-stage lead antibacterial product candidate omadacycline is a novel broad-spectrum antibiotic being developed for potential use as an empiric monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Empiric monotherapy refers to the use of a single antibacterial agent to begin treatment of an infection before the specific pathogen causing the infection has been identified. It has designed omadacycline to provide potential advantages over existing antibiotics including activity against antibiotic-resistant bacteria broad spectrum of coverage intravenous and oral formulations with once-daily dosing and a favorable safety and tolerability profile. The Companys second late-stage lead antibacterial product candidate sarecycline previously known as WC3035 is a novel once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea. It believes that based upon the data generated to-date sarecycline possesses favorable anti-inflammatory activity plus narrow-spectrum antibacterial activity relative to other tetracycline-derived molecules. It has exclusively licensed rights to sarecycline for the treatment of acne in the United States to Warner Chilcott now Actavis plc or Actavis while retaining rights in the rest of the world. Actavis has informed the Company that sarecycline entered Phase 3 clinical trials in December 2014 for acne. In addition it has granted Actavis an exclusive license to develop and commercialize sarecycline for the treatment of rosacea in the United States which converted to a non-exclusive license in December 2014 after Actavis did not exercise its development option with respect to rosacea. There are currently no clinical trials in rosacea under way. Actavis has announced that upon the closing their merger with Allergan Inc. and subject to board approval and ratification the new combined company will be called Allergan. The Company does not plan to develop or commercialize sarecycline itself but intends to out-license rest of world rights. Its potential competitors include large pharmaceutical and biotechnology companies specialty pharmaceutical companies and generic drug companies. The Company believes that its product candidates offer key potential advantages over competitive products that could enable its product candidates if approved to capture meaningful market share from its competitors. The Company registered the service marks and trademarks PARATEK and PARATEK PHARMACEUTICALS & DESIGN which it uses in connection with pharmaceutical research and development as well as product candidates. The PARACYCLINE mark is registered in the European Union and Japan. In addition it has also registered the service mark THE ANTIBIOTIC RESISTANCE COMPANY in the European Union and Japan which may be used in connection with the research and development of pharmaceuticals drugs and antibiotics and the test evaluation research and development of antibiotics and other pharmaceutical products respectively. In addition to regulations in the United States the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.
[야후 파이낸스 바로가기]
종목진단
고가 2.05 저가 1.95
종가 전일대비 등락률
1.97 ▼ -0.05 ▼ -2.48%
시가총액 52주 최고가 52주 최저가
1억 11.24 1.79
주식수 상장일 결산월
54백만 2014/11/03 12
매출 EPS PER BPS PBR DPS
분기 TTM 분기 TTM 분기 TTM 분기 TTM 분기 TTM 분기 TTM
0억 1억 -0.33 -1.08 -9.03 -2.75 -2.58 -2.17 -1.15 -1.37 0 0

* 데이터 기준일 : 2022/05/16, TTM: Trailing Twelve Month, 금액단위: USD

  • 90일
  • 1년
  • 5년
  • 롱텀
  • 시즈널
  • 뉴지엔벨

  • 이동평균선

    5일

    20일

    60일

    120일

  • 원래대로

엔벨 값 변경 - 이동평균 : 상밴드 : 하밴드 :
  • 재무제표
  • 랭크분석
  • 기업개요
일자(60일) A+ A 모멘텀 펀더멘탈 종합 엔벨위치 롱텀위치 대비 종가
2022/05/16 0 0 53 62 57 40 14 -0.05(▼-2.48%) 1.97
2022/05/13 0 1 78 54 66 45 16 0.14(▲7.45%) 2.02
2022/05/12 0 0 44 54 49 6 10 0.05(▲2.73%) 1.88
2022/05/11 0 0 28 54 41 0 8 -0.11(▼-5.67%) 1.83
2022/05/10 0 0 35 54 45 3 12 0.04(▲2.11%) 1.94
2022/05/09 0 0 23 54 38 0 10 -0.18(▼-8.65%) 1.90
2022/05/06 0 0 30 54 42 21 17 -0.08(▼-3.70%) 2.08
2022/05/05 0 0 36 54 45 36 19 -0.02(▼-0.92%) 2.16
2022/05/04 0 0 26 54 40 39 20 0.00 2.18
2022/05/03 0 0 31 54 42 34 19 -0.06(▼-2.68%) 2.18
2022/05/02 0 1 73 54 64 46 21 0.03(▲1.36%) 2.24
2022/04/29 0 0 45 54 50 37 20 -0.02(▼-0.90%) 2.21
2022/04/28 0 0 29 54 42 35 20 -0.02(▼-0.89%) 2.23
2022/04/27 0 0 46 54 50 31 21 0.05(▲2.27%) 2.25
2022/04/26 0 0 26 54 40 14 19 -0.12(▼-5.17%) 2.20
2022/04/25 0 0 51 54 53 23 23 0.10(▲4.50%) 2.32
2022/04/22 0 0 15 54 34 0 19 -0.09(▼-3.90%) 2.22
2022/04/21 0 0 28 54 41 0 22 0.02(▲0.87%) 2.31
2022/04/20 0 0 8 54 31 0 21 0.00 2.29
2022/04/19 0 0 4 54 29 0 21 -0.05(▼-2.14%) 2.29
2022/04/18 0 0 6 54 30 0 23 -0.21(▼-8.24%) 2.34
2022/04/14 0 0 11 53 32 0 29 -0.06(▼-2.30%) 2.55
2022/04/13 0 0 13 53 33 2 30 0.03(▲1.16%) 2.61
2022/04/12 0 0 11 53 32 0 29 -0.36(▼-12.24%) 2.58
2022/04/11 0 1 77 53 65 45 38 0.11(▲3.89%) 2.94
2022/04/08 0 0 29 52 41 25 36 -0.15(▼-5.03%) 2.83
2022/04/07 0 0 70 52 61 48 39 0.06(▲2.05%) 2.98
2022/04/06 0 0 35 52 44 37 38 -0.09(▼-2.99%) 2.92
2022/04/05 0 0 46 52 49 50 40 -0.08(▼-2.59%) 3.01
2022/04/04 0 1 80 53 66 60 41 0.15(▲5.10%) 3.09
2022/04/01 0 0 28 53 40 34 38 -0.03(▼-1.01%) 2.94
2022/03/31 0 0 26 53 39 35 38 0.00 2.97
2022/03/30 0 0 19 53 36 31 38 -0.06(▼-1.98%) 2.97
2022/03/29 0 0 43 53 48 39 40 0.02(▲0.66%) 3.03
2022/03/28 0 0 27 53 40 34 39 0.07(▲2.38%) 3.01
2022/03/25 0 0 6 53 30 20 37 -0.13(▼-4.23%) 2.94
2022/03/24 0 0 10 53 32 31 40 0.02(▲0.66%) 3.07
2022/03/23 0 0 4 53 28 22 40 -0.14(▼-4.39%) 3.05
2022/03/22 0 0 29 53 41 33 43 0.01(▲0.31%) 3.19
2022/03/21 0 0 23 53 38 29 42 0.00 3.18
2022/03/18 0 0 16 64 40 26 42 -0.09(▼-2.75%) 3.18
2022/03/17 0 0 46 64 55 37 44 0.15(▲4.81%) 3.27
2022/03/16 0 0 8 64 36 13 41 0.00 3.12
2022/03/15 0 0 11 64 38 7 41 -0.11(▼-3.26%) 3.12
2022/03/14 0 0 28 65 46 17 43 -0.26(▼-7.33%) 3.23
2022/03/11 0 1 72 65 68 50 48 -0.02(▼-0.57%) 3.48
2022/03/10 0 0 64 65 65 51 49 -0.26(▼-6.91%) 3.50
2022/03/09 1 1 96 65 81 87 54 0.37(▲10.91%) 3.76
2022/03/08 0 0 49 65 57 37 46 0.01(▲0.30%) 3.39
2022/03/07 0 0 49 65 57 31 46 0.03(▲0.90%) 3.38
2022/03/04 0 0 23 65 44 23 45 -0.03(▼-0.89%) 3.35
2022/03/03 0 0 17 65 41 22 46 -0.11(▼-3.15%) 3.38
2022/03/02 0 0 17 65 41 31 48 -0.04(▼-1.13%) 3.49
2022/03/01 0 0 20 65 42 30 49 0.01(▲0.28%) 3.53
2022/02/28 0 0 16 65 41 24 48 -0.05(▼-1.40%) 3.52
2022/02/25 0 0 18 65 42 29 49 -0.05(▼-1.38%) 3.57
2022/02/24 0 0 41 65 53 30 50 0.10(▲2.84%) 3.62
2022/02/23 0 0 28 65 47 13 48 -0.17(▼-4.61%) 3.52
2022/02/22 0 0 33 65 49 28 51 -0.07(▼-1.86%) 3.69
2022/02/18 0 0 33 65 49 32 53 0.03(▲0.80%) 3.76

* 금액단위: USD